| Bristol-Myers Squibb SA - Lenalidomid BMS 25 mg, Hartkapseln | | 68490 | | 07 | | Lenalidomid BMS 25 mg | | Hartkapseln | | L04AX04 | | Lenalidomide | | 14.06.2021 | | |
| | Composition | | lenalidomidum 25 mg, lactosum 200 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.8 mg, magnesii stearas, Kapselhülle: gelatina, E 171, Drucktinte: lacca, propylenglycolum, E 172 (nigrum), kalii hydroxidum, pro capsula. | | Packungsbestandteile | | Capsules | | | | | Principe actif | Concentr. |
|---|
| Lenalidomidum | 25 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Lenalidomidum | 25 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| (Nigrum) | | | | Carmellosum Natricum Conexum | | | | Cellulosum Microcristallinum | | | | E 171 | | color. | | E 172 | | color. | | Gelatina | | Kapselhülle | | Kalii Hydroxidum | | | | Lacca | | Drucktinte | | Lactosum | 200 mg | | | Magnesii Stearas | | | | Pro Capsula | | | | Propylenglycol | | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 007 | 21 | 861.14 | 952.95 | A | LS | Oui |
|
|
